Compare Globus Medical Inc. Class A Common Stock (GMED) vs Smurfit WestRock plc Ordinary Shares (SW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Smurfit WestRock plc Ordinary Shares — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while Smurfit WestRock plc Ordinary Shares trades at $41.11 (market cap $21.37B). The key difference: Smurfit WestRock plc Ordinary Shares is far larger — about 2.1× Globus Medical Inc. Class A Common Stock's market cap, and Smurfit WestRock plc Ordinary Shares pays a 4.44% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Smurfit WestRock plc Ordinary Shares for 5 Days on average.
| GMED | SW | |
|---|---|---|
Market Cap | $10.25B | $21.37B |
Volume | 1,059,528 | 2,776,603 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $51.84 |
52-Week Low | $58.33 | $32.79 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $9.76B | $34.86B |
Dividend Yield | — | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Smurfit Westrock (SW) trades at $41.45, showing modest daily gains of 0.93% but facing technical bearish signals with 17 sell indicators versus 4 buys. The company reported three consecutive quarterly earnings misses amid cost pressures, though revenue remains stable above $31 billion. Recent strategic moves include the $420 million acquisition of CMPC's Chilean containerboard business to strengthen regional footprint and reduce costs.
Despite unanimous analyst buy ratings and a $71.50 price target suggesting 72% upside, SW faces execution risks from freight cost inflation and margin compression. The stock's high P/E ratio of 44.01 contrasts with weak profitability metrics (ROE 2.74%), creating a divergence between valuation and fundamental performance that warrants cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Smurfit WestRock plc Ordinary Shares
Smurfit WestRock plc is an Ireland-headquartered packaging company that manufactures corrugated containers and consumer packaging from containerboard and paperboard, operating mills, converting plants, and recycling facilities across more than 40 countries.
Read more on SW →
